● Pharmacogenetics
-
ʻO ke kanaka CYP2C9 a me VKORC1 Gene Polymorphism
Pili kēia kit i ka in vitro qualitative detection of polymorphism o CYP2C9*3 (rs1057910, 1075A>C) a me VKORC1 (rs9923231, -1639G>A) i loko o ka genomic DNA o ke kanaka holookoa koko samples.
-
Kanaka CYP2C19 Gene Polymorphism
Hoʻohana ʻia kēia pahu no ka ʻike in vitro qualitative o ka polymorphism o CYP2C19 genes CYP2C19*2 (rs4244285, c.681G>A), CYP2C19*3 (rs4986893, c.636G>A), CYP2C19*248 (rs4244285, c.681G>A), CYP2C19*3 (rs4986893, c.636G>A), CYP2C19*248 (rs4012,608). >T) i ka DNA genomic o nā laʻana koko holoʻokoʻa kanaka.
-
Kanaka Leukocyte Antigen B27 Nucleic Acid
Hoʻohana ʻia kēia pahu no ka ʻike qualitative o ka DNA i nā subtypes antigen leukocyte kanaka HLA-B*2702, HLA-B*2704 a me HLA-B*2705.
-
MTHFR Gene Polymorphic Nucleic Acid
Hoʻohana ʻia kēia pahu no ka ʻike ʻana i nā pae hoʻololi ʻelua o ka gene MTHFR.Hoʻohana ka pahu i ke koko holoʻokoʻa o ke kanaka ma ke ʻano he laʻana hoʻāʻo e hāʻawi i kahi loiloi qualitative o ke kūlana mutation.Hiki iā ia ke kōkua i nā kauka e hoʻolālā i nā hoʻolālā lapaʻau kūpono no nā ʻano like ʻole o kēlā me kēia kanaka mai ka pae molekala, i mea e hōʻoia ai i ke olakino o nā maʻi i ka nui loa.
